Arkolith/Insider Trading/CINC/Form 4

de Garidel Marc

Chief Executive Officer, DirectorCinCor Pharma, Inc. (CINC) · full profile →Form 4 · filed Feb 24, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 24, 2023Disposed to issuer(D)200K——0
Feb 24, 2023Tender(U)13K——200K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 24, 2023Disposed to issuer(D)602K——0
Feb 24, 2023Disposed to issuer(D)726K——0

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-012890) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML